Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapyEfstathios Kastritis, Meletios Α. Dimopoulos, Theofanis Apostolou et al.|American Journal of Hematology|2017Cited by 73
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosisEfstathios Kastritis, Giovanni Palladini, Ioannis Papassotiriou et al.|Blood|2018Cited by 67
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trialElisabeth Livingstone, Dirk Schadendorf, Helen Gogas et al.|European Journal of Cancer|2023Cited by 15
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced <i>BRAF<sup>V600</sup></i>-positive melanoma: Interim analysis of the ImmunoCobiVem study.Dirk Schadendorf, Elisabeth Livingstone, Helen Gogas et al.|Journal of Clinical Oncology|2022Cited by 7
Early switch from run-in with targeted to immunotherapy in advanced BRAF-positive melanoma: final results of the randomised phase II ImmunoCobiVem trialE. Livingstone, Dirk Schadendorf, H.J. Gogas et al.|ESMO Open|2025Cited by 4